2 Compounds in Coffee Seen to Slow Growth of Prostate Cancer in Early Study

2 Compounds in Coffee Seen to Slow Growth of Prostate Cancer in Early Study
Two compounds found in coffee might be able to slow the growth and migration of prostate cancers, a pilot study conducted in drug-resistant cancer cells and a mouse model report. As such, two possible therapeutic candidates for drug-resistant prostate cancers may have been identified in this work, which also helps in explaining why findings in some studies show regular coffee drinkers with lower prostate cancer risks. The compounds, kahweol acetate and cafestol, were seen, in a dose-dependent manner, to slow the progression of prostate tumors that are resistant to standard therapy in mice. Researchers in Japan plan to continue with this line of study. The study, “Coffee diterpenes kahweol acetate and cafestol synergistically inhibit the proliferation and migration of prostate cancer cells,” was published in The Prostate and presented at the recent 2019 Annual European Association of Urology (EAU) Congress, held in Barcelona. Some evidence suggests a link between drinking certain types of coffee and a lower risk of some cancers, including prostate cancer. A grouped analysis of studies, which included 864,012 subjects, estimated that regular coffee drinkers were 11% less likely to develop prostate cancer than those who rarely or never drank it. But coffee is made of a complex mixture of more than 1,000 compounds, and we know little about which are responsible for its potential anti-cancer effects. This gap sparked the attention of a team of scientists at Kanazawa University Graduate School of Medical Science. They investigated in more detail the anti-cancer activity of six coffee compounds: kahweol acetate, cafestol, caffeine, caffeic acid, chlorogenic acid, and trigonelline hydrochloride. Several human prostate cancer cell lines, cultured in
Subscribe or to access all post and page content.